首页> 外国专利> NON-BETA LACTAM ANTIBIOTICS

NON-BETA LACTAM ANTIBIOTICS

机译:非BETA内酰胺类抗生素

摘要

The invention provides a newly discovered oxadiazole class of antibiotics. The oxadiazoles impair cell-wall biosynthesis and exhibit activities against the Gram-positive bacteria such as the bacterium Staphylococcus aureus, including methicillin-resistant S. aureus (MRSA) and vancomycin-resistant and linezolid-resistant S. aureus. For example, 5-(1H-indol-5-yl)-3-(4-(4-(trifluoromethyl)phenoxy)phenyl)-1,2,4-oxadiazole (antibiotic 75b) was efficacious in a mouse model of MRSA infection, exhibiting a long half-life, a high volume of distribution, and low clearance. Antibiotic 75b antibiotic is bactericidal and is orally bioavailable. This class of antibiotics can be used as a therapeutic agent against infections by Gram-positive bacteria such as MRSA.
机译:本发明提供了新发现的恶二唑类抗生素。恶二唑会损害细胞壁的生物合成,并表现出对革兰氏阳性细菌(如金黄色葡萄球菌)(包括耐甲氧西林的 S)的活性。金黄色葡萄球菌(MRSA)和耐万古霉素和耐利奈唑胺的 S。金黄色。例如,5-(1H-吲哚-5-基)-3-(4-(4-(三氟甲基)苯氧基)苯基)-1,2,4-恶二唑(抗生素75b)在MRSA小鼠模型中有效感染,表现出长的半衰期,高分布量和低清除率。抗生素75b抗生素具有杀菌作用,可以口服生物利用。这类抗生素可用作抗革兰氏阳性细菌(例如MRSA)感染的治疗剂。

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号